Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. [electronic resource]
Producer: 20120601Description: 1420-9 p. digitalISSN:- 1097-0215
- Animals
- Cell Line, Tumor
- Cell Movement -- drug effects
- Cell Proliferation -- drug effects
- Cysteine -- analogs & derivatives
- Farnesol -- analogs & derivatives
- Lymphangioleiomyomatosis -- drug therapy
- Lymphocytes, Null
- Mice
- Mice, Nude
- Monomeric GTP-Binding Proteins -- antagonists & inhibitors
- Mutation -- genetics
- Neuropeptides -- antagonists & inhibitors
- Phosphorylation -- drug effects
- Ras Homolog Enriched in Brain Protein
- Rats
- Ribosomal Protein S6 Kinases -- metabolism
- Salicylates -- pharmacology
- Tuberous Sclerosis Complex 2 Protein
- Tumor Suppressor Proteins -- deficiency
- ras Proteins -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.